Systemic delivery of therapeutic peptides and proteins

International Journal of Pharmaceutics

Volumn 48, Issue 1-3, 1988, Pages 15-50

  Banga, Ajay K ^a   Chien, Yie W ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Biotechnology; Delivery route; Peptide; Protein; Protein analysis; Protein formulation

Indexed keywords

GONADORELIN DERIVATIVE; HEPARIN; INSULIN; INTERFERON; PEPTIDE; PROTEIN; VASOPRESSIN;

ANIMAL EXPERIMENT; DRUG ADMINISTRATION; DRUG ADSORPTION; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; MINIPUMP; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; TOPICAL DRUG ADMINISTRATION;

EID: 0023790699     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(88)90246-3     Document Type: Review

References (302)

1. Analysis of bovine, porcine and human insulins in pharmaceutical dosage forms and drug delivery systems
2. Stability of insulin mixtures in diposable insulin syringes
3. Glucose sensitive membranes for controlled delivery of insulin: insulin transport studies
4. Protein derivatives: Part I
5. Protein derivatives: Part II
6. 6 LHRH, a decapeptide, onto glass and other surfaces
7. Nasal absorption of nafarelin acetate, the decapeptide LHRH, in rhesus monkeys
8. LHRH analogs — a case history. Pharmaceutical considerations in the use of peptides and proteins
9. Orally administered liposome entrapped insulin in diabetic animals
10. Atrial natriuretic factor: a new hormone of cardiac origin
11. Comparison of nasal rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter
12. Iontophoretic delivery of drugs: Fundamentals, developments and biomedical applications
13. Biotech industry moving pharmaceutical products to market
14. A radioreceptor assay for pharmaceutical preparations of insulin
15. Radioimmunoassay of arginine vasopressin in human plasma
16. In-vitro and in-vivo release of insulin from porous polymeric implants
17. Clinical evaluation of injectable biodegradable contraceptive system
18. Controlled release delivery systems for hormones: a review of their properties and current therapeutic use
19. Determination of the dimensions of particles in suspensions of zinc-insulin by a turbidity spectrum method
20. Hypophysical responses to continuous and intermittent delivery of hypothalamic gonadotropin releasing hormone
21. Stability of insulin preparations
22. The encapsulation of insulin in erythrocytes
23. Long term and constant release of vasopressin from accurel tubing: implantation in the Brattleboro rat
24. Considerations for the quality control of biotechnology products
25. Prevention of insulin aggregation of dicarboxylic amino acids during prolonged infusion
26. Controlled release of insulin from polymer matrices: In-vitro kinetics
27. Controlled release of insulin from polymer matrices: control of diabetes in rats
28. Long term use of intravenous immune globulin in patients with primary immunodeficiency diseases: inadequacy of current dosage practices and approaches to the problem
29. Comparison between the ionttophoretic and passive transport of thyrotropin releasing hormone across excised nude mouse skin
30. Solid-phase radioimmunoassay of insulin
31. Chemical, physical and biologic properties of biosynthetic human insulin
32. New drugs and drug-delivery systems in the year 2000
33. Transdermal iontophoretic delivery of therapeutic peptides/proteins: (I) Insulin
34. Use of jet insulin injector in diabetes mellitus therapy
35. Sintering technique for the preparation of polymer matrices for the controlled release of macromolecules
36. Absorption of insulin from the human small intestine
37. Stimulation of the normal menstrual cycle in Kallman's syndrome by pulsatile administration of luteinizing hormone-releasing hormone (LHRH)
38. Therapeutic applications of luteinizing- hormone-releasing-hormone and its analogs
39. Plasma radioactivity after rectal instillation of radioiodine-labelled human albumin in normal subjects and in patients with ulcerative colitis
40. Advantage of a new colloidal drug delivery system in the insulin treatment of streptozotocin-induced diabetic rats
41. Disc electrophoresis II. Method and application to human serum proteins
42. Control of diabetes with polyacrylamide implants containing insulin
43. Diffusion in polymer gel implants
44. Rectal bioavailability of lidocaine in rats: absence of significant first-pass elimination
45. Avoidance of first-pass' elemination of rectally administered lidocaine in relation to the site of absorption in rats
46. Biotechnology in Europe
47. The entrapment of biologically active substances into liposomes. I. Effects of oral administration of liposomally entrapped insulin in normal rats
48. Controlled release of antithrombotic agents from polymer-matrices
49. Heparin/Polymers for the prevention of surface thrombosis
50. Biotechnology: Present and future roles in the pharmaceutical industry
51. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin
52. Intranasal administration of human pancreatic tumor GH-releasing factor-40 stimulates GH-release in normal men
53. High resolution of two-dimensional electrophoresis of proteins
54. Insulin dissociation at alkaline pH
55. Stability of bovine insulin
56. HPLC as a replacement for the animal response assays for insulin
57. Intranasal admixture of insulin efficacy and mechanism
58. The pathway for insulin absorption across the nasal mucosal membrane in the presence of the absorption enhancer sodium taurodihydrofusidate
59. Effect of pretreatment with 0.9% sodium chloride or insulin solutions on the delivery of insulin from an infusion system
60. Scientific and regulatory aspects of macromolecular drugs and devices
61. Developing functionally relevant standards for protein and polypeptide drugs produced using biotechnological methods
62. Intravenous gamma globulin therapy
63. Nasal absorption of insulin: enhancement by hydrophobic bile salts
64. Chemical stability of insulin in a delivery system environment
65. Pharmaceutical applications of polymorphism
66. Zinc insulin preparations for single daily injection
67. Clinical trials of a new insulin jet injector allowing the mixing of two types of insulin
68. Intranasal drug delivery by spray and drops
69. Genetic engineering and the pharmaceutical industry
70. Human tolerance and histologic effects of long term administration of intranasal interferon 2
71. Experience with and acceptance of multiple daily insulin injections using novopen, a new insulin delivery device
72. Fast atom bombardment mass spectrometry and its application to the analysis of some peptides and proteins
73. Peptides and proteins: pharmacokinetics and analytical considerations
74. Iontophoretic delivery of peptides and proteins; in vitro studies and mechanistic analysis
75. Adsorption of insulin to glass
76. Clinical studies with jet injection: New method of drug administration
77. Nasal absorption of insulin in dogs
78. Effects of surfactants on the nasal absorption of insulin in rats
79. Mechanisms for the enhancement of the nasal absorption of insulin by surfactants
80. Clinical significance of insulin adsorption to polyvinyl chloride infusion systems
81. Differential expression of human inferferon genes
82. Induction of puberty in men by long term pulsatile administration of low dose gonadotropin releasing hormone
83. Swelling behaviour of glucose sensitive membranes
84. A bioresponsive membrane for insulin delivery
85. Magnetic modulation of macromolecules from polymers
86. Magnetic modulation of insulin release in diabetic rats
87. Controlled release of macromolecules from silicone elastomer
88. Devices for macromolecules
89. Ocular drug delivery of progesterone using a bioadhesive polymer
90. The oral bioavailability of peptides and related drugs
91. Circadian variations in insulin and alloxan sensitivity noted in blood glucose alterations in normal and diabetic mice
92. Rectal absorption of insulin suppositories in rabbits
93. Success, relapse and failure after intranasal LHRH treatment of cryptorchidism in 55 prepubertal boys
94. Effect of intranasal LHRH therapy on plasma LH, FSH and testosterone, and relation of clinical results in prepubertal boys with cryptorchidism
95. Ocular peptide delivery: proteolytic activities in ocular tissues of the albino rabbit
96. New mucosal dosage forms of insulin
97. Biotech trends in the Japanese pharmaceutical industry
98. Polypeptide growth factors
99. Polymerization pattern of insulin at pH 7.0
100. Self-regulating insulin delivery systems I Synthesis and characterization of glycosylated insulin
101. Self-regulating insulin delivery systems III. In vivo studies, Advances in drug delivery systems
102. Human insulin from recombinant DNA technology
103. Challenges in formulation design and delivery of protein drugs
104. Study of enamine derivatives of phenylglycine as adjuvants for the rectal absorption of insulin
105. Control of blood glucose levels in alloxan-diabetic rabbits by iontophoresis of insulin
106. Enkephalin hydrolysis in homogenates of various absorptive mucosae of the albino rabbit: similarities in rates and involvement of aminopeptidases
107. Hydrolysis of enkephalins in anterior segment tissue homogenates of the albino rabbit eye
108. No reduction of blood glucose in diabetic rats after oral administration of insulin liposomes prepared under acidic conditions
109. The use of cholesterol matrix pellets implants for early studies on the prolonged release in animals of agonist analogues of luteinizing hormone releasing hormone
110. Feasibility studies on the controlled release of an LHRH analogue from subcutaneously injected polymeric microspheres: Early in vivo studies
111. Microencapsulation of the peptide Nafarelin acetate for controlled release
112. The absorption of insulin from various regions of the rat intestine
113. Effect of enamine derivatives on the rectal absorption of insulin in dogs and rabbits
114. Self-regulating insulin delivery system — A chemical approach
115. Studies on liposome-encapsulated heparin
116. The use of continuous insulin delivery systems in treatment of diabetes mellitus
117. The chemistry and biochemistry of insulin
118. Buserlin: Contraception through nasal spray
119. Specific receptors for vasopressin in the pituitary gland: evidence for down-regulation and desensitisation to adrenocorticotropin-releasing factors
120. FDA, OSHA and EPA regulation of the recombinant DNA technology
121. Magnetically modulated drug delivery systems
122. Controlled long term release of small peptide hormones using a new microporous polypropylene polymer: its application for vasopressin in the Brattleboro rat and potential perinatal use
123. 3H] vasopressin for in-vivo studies of controlled delivery from an Accurel/Collodion device in the Brattleboro rat
124. Insulin bolus given by sprinkler needle: improved absorption and glycaemic control
125. In-vitro and in-viro release of insulin from poly(lactic acid) microbeads and pellets
126. Polymers for the sustained release of proteins and other macromolecules
127. Sustained release of macromolecules from polymers
128. Controlled release and magnetically modulated systems for macromolecular drugs
129. Development of an aerosol dosage form containing insulin
130. Topical ocular drug delivery: recent advantages and future perspectives
131. Ocular drug bioavailability from topically applied liposomes
132. Peptide and protein drug delivery: Opportunities and challenges
133. Topical drug delivery: recent developments and future challenges
134. Metabolic and permeation barriers to the ocular absorption of topically applied enkephalins in albino rats
135. Macromolecular drug absorption in the albino rabbit eye
136. Ophthalmic delivery of peptides and proteins
137. Nasal peptide and protein absorption promoters: aminopeptidase inhibition as a predictor of absorption enhancement potency of bile salts
138. Peptide and protein drug delivery systems
139. Long term follow up of diabetic patients using insulin infusion pumps: considerations for future clinical application
140. Parenteral products
141. Biodegradable microcapsules for contraceptive steroids
142. Induction of ovulation with chronic intermittent (pulsatile) administration of LHRH in women with hypothalamic and hyperprolactinemic amenorrhea
143. Influence of drug properties and routes of drug administration on the design of sustained and controlled release systems
144. Development of a new jet injection for insulin therapy
145. Blood glucose control in diabetic rats by transdermal iontophoretic delivery of insulin
146. Effect of rectal suppository formulation on the release of insulin and on the glucose plasma levels in dogs
147. Effect of suppository shape on the systemic availability of rectally administered insulin and sodium salicylate
148. Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep
149. Physical stability of insulin formulations
150. Evidence for insulin degradation by muscle and fat tissue in an insulin resistant diabetic patient
151. Analytical aspects in the development of peptide and protein drugs
152. Analytical aspects in the development of peptide and protein drugs
153. Use of specific routes of administration for peptides and proteins: parenteral
154. Development of aggregation resistant insulin formulations
155. Binding of human insulin to burette administration sets
156. Derivatizing reagents for high-performance liquid chromatography detection of peptides at the picomole level
157. Pharmacological studies on elastin peptides (kappa-elastin). Blood clearance, percutaneous penetration and tissue distribution
158. Inhibition of respiratory virus infection by locally applied interferon
159. Self adhesive patches for buccal delivery of peptides
160. Biopharmaceutical study of insulin suppositories
161. Electro-osmotic transdermal drug delivery, 1987 conference proceedings on the latest developments in drug delivery systems
162. Recombinant DNA as a paradigm of new technology: its impact on regulation by the Food and Drug Administration
163. Prevention of adsorption of protein on controlled-pore glass with amino acid buffer
164. Estimation of adsorption of drugs and proteins on glass surfaces with controlled pore glass as a reference
165. Decreased activity of proteins absorbed onto glass surfaces with porous glass as a reference
166. Immunoassay of insulin: two antibody system
167. Pharmaceutical studies of polyacrylic acid aqueous gel bases: absorption of insulin from polyacrylic acid aqueous gel bases following rectal administration in alloxan diabetic rats and rabbits
168. Enhancement of rectal absorption of insulin in polyacrylic acid aqueous gel bases containing long chain fatty acids in rats
169. 1,7]-eel calcitonin in rats using polyacrylic acid aqueous gel base
170. 1,7]-eel calcitonin in rats
171. Enhancement of nasal absorption of insulin and calcitonin using polyacrylic acid gel
172. Insulin administered intranasally as an insulin bile salt aerosol: Effectiveness and reproducibility in normal and diabetic subjects
173. Intranasal insulin delivery: Structure-function studies of absorption enhancing adjuvants
174. Hypoglycemia after liposomized insulin in the rat
175. Analysis of solvent-mediated conformational changes of insulin by radioimmunoassay (RIA) techniques
176. Adhesive topical drug delivery system
177. Mucosal adhesive dosage forms
178. Topical mucosal adhesive dosage forms
179. Successful treatment of extremely brittle, insulin dependent diabetes with a novel subcutaneous insulin pump regimen
180. Preformulation studies on recombinant tissue plasminogen activator
181. Enhanced rectal absorption of insulin and heparin in rats in the presence of non surfactant adjuvants
182. Enhancement of rectal absorption of insulin using salicylates in dogs
183. Effect of aprotinin on the rectal delivery of insulin
184. Adjuvant effects of glyceryl esters of acetoacetic acid on rectal absorption of insulin and inulin in rabbits
185. Enhanced bioavailability of insulin after rectal administration with enamine as adjuvant in depancreatized dogs
186. Trials of rectal insulin suppositories in healthy humans
187. An effective formulation for an insulin suppository; examination in normal dogs
188. Nasal delivery: a revolution in drug administration
189. Analysis of insulins by high-performance liquid chromatography III. Determination of insulins in various preparations
190. Protein purification: past, present and future
191. Use of liposomes to aid intestinal absorption of entrapped insulin in normal and diabetic dogs
192. Conformation of proinsulin. A comparison of insulin and proinsulin self-association at neutral pH
193. 2]-Met-Enkephalinamide: a potent long lasting synthetic pentapeptide analgesic
194. The purification and manufacture of human interferons
195. Development of a metered-dose nebulizer for intranasal peptide administration
196. Regulatory considerations for products derived from the new biotechnology
197. Regulatory considerations for products derived from the new biotechnology
198. Insulin adsorption by glass infusion bottles, polyvinyl chloride infusion containers and intravenous tubing
199. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia
200. Insulin given intranasally induced hypoglycemia in normal and diabetic subjects
201. Stability of proteins: small globular proteins
202. Minimizing the aggregation of neutral insulin solutions
203. Rectal administration of insulin
204. Pharmacology of bradykinin and related kinins
205. Electrophoretic properties of pituitary gonadotropins as studied by electrofocussing
206. Pump delivered insulin and home monitored blood glucose in a diabetic patient: retrospective and chronophysiologic evaluation of 3-year time series
207. Polymers for sustained macromolecule release: procedures to fabricate reproducible delivery systems and control release kinetics
208. Constraints of nonparenteral routes of administration
209. Iontophoresis and promoted drug absorption
210. Protein drugs: a revolution in therapy?
211. A new approach to the oral administration of insulin and other peptide drugs
212. Vasopressin: a model for the study of effects of additives on the oral and rectal administration of peptide drugs
213. Intranasal aerosolized insulin: Mixed meal studies and long term use in type I diabetes
214. Determination of total and encapsulated insulin in a vesicle formulation
215. Feasibility studies on the controlled release of an LHRH analogue from subcutaneously injected polymeric microspheres: Formulation characteristics
216. Controlled release of a luteinizing hormone releasing hormone analogue from Poly(d,l-lactide-Co-Glycolide) microspheres
217. Prevention of insulin self-association and surface adsorption
218. Self-regulating insulin delivery systems II In-vitro studies
219. Purified interferon as protection against rhinovirus infection
220. Insulin delivery: how, when, where
221. Protein chemistry as related to cosmetics and toiletries
222. Controlled release micropump for insulin administration
223. Insulin delivery at variable rates from a controlled release micropump
224. The effectiveness and comparison of human and bovine long-acting insulins
225. In vitro characterization of a self-regulating insulin delivery system
226. A model of the kinetics of insulin in man
227. Short-term treatment of alloxan diabetic rats with intrajejunal administration of water-in-oil-in-water insulin emulsions
228. Formulation design of protein pharmaceuticals
229. Facilitated transdermal transport of insulin
230. Nonparenteral administration of peptides and protein drugs
231. Transdermal iontophoretic delivery of insulin for blood glucose control in diabetic rabbits
232. Sintered polymers for sustained macromolecular drug release
233. Biological investigation of suppositories with insulin and lidase
234. Radioreceptor assay for insulin formulations
235. Chronic pulsatile low dose GnRH therapy for induction of testosterone production and spermatogenesis in a man with secondary hypogonadotrophic hypogonadism
236. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction
237. Coronary thrombolysis with facilitated absorption of intramuscularly injected tissue-type plasminogen activator
238. Intranasal application of luteinizing hormone-releasing hormone
239. Effect of liposomally entrapped insulin administered per os on the blood sugar level in normal and experimentally diabetic rats
240. Potential novel methods for insulin administration: Iontophoresis
241. Thermal stability of insulin made from zinc insulin crystals
242. Separation and partial purification of the protein hormone from human pituitary glands
243. Studies of the heterogeneity of human pituitary LH by fast protein liquid chromatography
244. Effect of storage temperature on stability of commercial insulin preparations
245. Functional and structural characteristics of EGF and its receptor and their relationship to transforming proteins
246. Role of epidermal growth factor in carcinogenesis
247. Aminopeptidase activity in the albino rabbit extraocular tissues relative to the small intestine
248. Ocular aminopeptidase activity and distribution in the albino rabbit
249. Nasal delivery of polypeptides I: Nasal absorption of enkephalins in rats
250. Intranasal delivery of peptides and proteins
251. High performance liquid chromatographic assay for thyrotropin releasing hormone and benzyl alcohol in injectable formulation
252. Transdermal modulated delivery of polypeptides: Effect of DC pulse wave form on enhancement
253. Insulin: a case study in the emergence of collaborative pharmacomedical research
254. Emerging trends in biotechnology: A perspective from the pharmaceutical industry
255. Bradykinin Radioimmunoassay
256. A radioimmunoassay for bradykinin in plasma and synovial fluid
257. Normalization of plasma glucose in juvenile diabetics by subcutaneous administration of insulin with a portable infusion pump
258. Prominent circadian absorption of intranasal salmon calcitonin (SCT) in healthy subjects
259. Mortality among diabetic patients using continuous subcutaneous insulin infusion pumps
260. Optimum administration of insulin: a complex story
261. A study of permeability of gingival pocket epithelium to albumin in guinea pigs and Norwegian pigs
262. In vitro penetration of tritiated dextrans through rabbit oral mucosa
263. New hydrophilic vehicle enabling rectal and vaginal absorption of insulin, heparin, phenol red and gentamicin
264. Effective intestinal absorption of insulin in diabetic rats using a new formulation approach
265. Promoted rectal absorption of insulin: formulation parameters involved in the absorption from hydrophilic bases
266. Targeted enteral delivery of insulin to rats
267. The permeability of skin to albumin, dextrans and polyvinylpyrrolidone
268. Nature of insulin binding to plastic bags
269. Oral administration of liposomally-entrapped heparin to beagle dogs
270. Buccal controlled delivery of peptides
271. In-vivo assessment of long acting formulations of luteinizing hormone-releasing hormone analogs
272. A piezoelectric micropump for insulin delivery
273. Liposome-collagen gel matrix: a novel sustained drug delivery system
274. Oral ingestion of insulin liposomes: effects of the administration route
275. Jet injection of insulin versus the syringe and needle method
276. The fate of the surface heparin of GBH-coated plastics after exposure to the blood stream
277. Resorption of alpha amylase upon buccal application
278. Insulin across respiratory mucosae by aerosol delivery
279. Improved glycerol-insulin solutions for use in implantable pumps
280. Interferon kinetics and adverse reactions after intravenous, intramuscular and subcutaneous injection
281. Liposomes for oral administration of drugs
282. Insulin suppository: enhanced rectal absorption of insulin using an enamine derivative as a new promoter
283. Radioimmunoassay methodology: application to problems of heterogeneity of peptide hormones
284. The effectiveness of rectal administration of insulin suppository in normal and diabetic subjects
285. The effect of rectal administration of insulin on short term treatment of alloxan diabetic dogs
286. Enhanced rectal bioavailability of polypeptides using sodium 5-methoxysalicylate as an absorption promoter
287. Bile salts promote the absorption of insulin from the rat colon